Tech Company Inital Public Offerings
Aprea Therapeutics IPO
Based in Boston, Aprea Therapeutics completed its IPO.
Transaction Overview
Company Name
Announced On
10/2/2019
Transaction Type
IPO
Amount
$85,500,000
Proceeds Purpose
The firm plans to use the net proceeds from the IPO as follows: to fund our preclinical and clinical development of APR-246, including our Pivotal Phase 3 trial in MDS, our ongoing Phase 1b/2 trials in MDS/AML, our Phase 2 trial in post-transplant maintenance therapy for MDS/AML, and our AML clinical trials; to fund manufacturing activities for APR-246; to fund research and development activities for APR-548, including ongoing IND-enabling studies and a first-in-human clinical trial; and the remainder to fund general research and development activities, working capital and other general corporate activities.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
535 Boylston St.
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Undisclosed
Website
Email Address
Overview
Aprea Therapeutics (Nasdaq: APRE) is a Stockholm, Sweden and Boston, Massachusetts-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein, p53.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christian Schade
Chief Medical Officer
Eyal Attar
Chief Scientific Officer
Lars Abrahmsen
VP - Bus. Development
Gregory Korbel
Browse more venture capital transactions:
Prev: 10/2/2019: 7shifts venture capital transaction
Next: 10/3/2019: CareStack venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs